Melanotan I is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer. Melanotan I is fda-approved as scenesse for epp only (prescription). not approved for cosmetic tanning. As with any research compound, individual responses vary.
Is Melanotan I Safe?
Safety is the most important consideration with any research compound. Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist with a safety profile established through preclinical research.
Multiple Phase II/III clinical trials. FDA-approved in 2019 for erythropoietic protoporphyria (EPP) as Scenesse — the only Melanotan with full regulatory approval and extensive human safety data.
What Are the Known Side Effects of Melanotan I?
Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.
These effects are based on preclinical data and community reports at standard dosages of 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing). Higher doses generally increase both the likelihood and severity of side effects.
Are Melanotan I Side Effects Dose-Dependent?
Most reported Melanotan I side effects are dose-dependent — meaning they're more likely at higher doses and less likely at the lower end of the 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) range.
This is why starting at the minimum effective dose and titrating up is the standard approach. With a half-life of ~2 hours circulating; implant provides 2-month depot release, any adverse effects will typically resolve within a few half-life periods after discontinuation.
What About Long-Term Melanotan I Use?
Long-term safety data for Melanotan I is limited, as with most research peptides. Standard cycles run 60-day implant cycles; 4-8 weeks injection cycles.
Melanotan I is fda-approved as scenesse for epp only (prescription). not approved for cosmetic tanning. Extended use beyond recommended cycles should be approached with caution.
Does Melanotan I Interact With Other Compounds?
Used as standalone; not typically combined with other melanocortin peptides.
When stacking peptides, be aware that combining multiple compounds increases the total side-effect surface area. Monitor closely when introducing any new compound.
How Can You Minimize Melanotan I Side Effects?
Start at the lower end of the dosage range (16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing)). Use proper reconstitution and injection technique to minimize injection site reactions. Store correctly (lyophilized at -20°C, reconstituted at 2-8°C) to maintain purity.
Source only from vendors with third-party COA testing — contaminated or mislabeled products are a significant source of unexpected adverse effects.
What Is the Bottom Line on Melanotan I Safety?
Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer. Overall, Melanotan I is considered a compound requiring careful monitoring at standard research doses.
Read our Melanotan I dosage guide for protocols designed to minimize risk.
Complete Guide
Melanotan I : Benefits, Dosage, Side Effects & Research
Related Reading
- Melanotan I Dosage Guide
- Melanotan I Benefits
- Melanotan I Stacking Guide
- Melanotan I Cycle Guide
- Melanotan I Research
- ARA-290 Complete Guide
Calculate Your Melanotan I Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Melanotan I.
Open Calculator →Research-Grade Sourcing
If you're going to research Melanotan I, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Melanotan I?
Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Synthetic α-MSH analog developed to stimulate melanin production through selective MC1R activation. It is researched for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
What is the recommended Melanotan I dosage?
Common dosages: 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) via subcutaneous implant (approved) or subcutaneous injection. Cycle length: 60-day implant cycles; 4-8 weeks injection cycles. Half-life: ~2 hours circulating; implant provides 2-month depot release. Use our peptide calculator for exact reconstitution math.
What are the side effects of Melanotan I?
Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.
Is Melanotan I safe?
Melanotan I has shown a preliminary safety profile in research. FDA-approved as Scenesse for EPP only (prescription). Not approved for cosmetic tanning. All research should follow appropriate safety protocols.